期刊
ACTA PHARMACEUTICA SINICA B
卷 11, 期 10, 页码 3165-3177出版社
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2021.04.019
关键词
Bacteria-mediated cancer therapy; Salmonella; VNP20009; Flagellum; Flagellin; TLR5; NF-kappa B; Cancer immune therapy
资金
- Jiangsu Provincial Nature Science Foundation (China) [BK20192005]
- National Natural Science Foundation of China [81630092, 81903143, 81802338, 82072646]
- Zhejiang Provincial Natural Science Foundation of China for Distinguished Young Scholars [LR21H160001]
- Start-up Grant of HZNU (China) [4125C5021820470]
The study confirmed the active involvement of host immune response in Salmonella-mediated cancer therapy, highlighting the key role of flagella in activating the host immune response.
Salmonella: mediated cancer therapy has achieved remarkable anti-tumor effects in experimental animal models, but the detailed mechanism remains unsolved. In this report, the active involvement of the host immune response in this process was confirmed by comparing the tumor-suppressive effects of Salmonella in immunocompetent and immunodeficient mice bearing melanoma allografts. Since flagella are key inducers of the host immune response during bacterial infection, flagella were genetically disrupted to analyse their involvement in Salmonella-mediated cancer therapy. The results showed that flagellum-deficient strains failed to induce significant anti-tumor effects, even when more bacteria were administered to offset the difference in invasion efficiency. Flagella mainly activate immune cells via Flagellin/Toll-like receptor 5 (TLR5) signalling pathway. Indeed, we showed that exogenous activation of TLR5 signalling by recombinant Flagellin and exogenous expression of TLR5 both enhanced the therapeutic efficacy of flagellum-deficient Salmonella against melanoma. Our study highlighted the therapeutic value of the interaction between Salmonella and the host immune response through Flagellin/TLR5 signalling pathway during Salmonella-mediated cancer therapy, thereby suggesting the potential application of TLR5 agonists in the cancer immune therapy. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据